Single and combination nonhormonal chemotherapy in breast cancer
نویسندگان
چکیده
منابع مشابه
Introduction. Single-agent or combination chemotherapy in metastatic breast cancer.
It is fair to say that combination chemotherapy is the standard of care in metastatic breast cancer. In many ways, however, the burden of proof that it is the standard of care remains with those who advocate combination therapy. Some of the push to consider combination therapy as the standard is provided by a meta-analysis of trials comparing single-agent and combination therapy in this setting...
متن کاملSingle-Agent or Combination Chemotherapy in Metastatic Breast Cancer
It is fair to say that combination chemotherapy is the standard of care in metastatic breast cancer. In many ways, however, the burden of proof that it is the standard of care remains with those who advocate combination therapy. Some of the push to consider combination therapy as the standard is provided by a meta-analysis of trials comparing single-agent and combination therapy in this setting...
متن کاملPaclitaxel-based combination chemotherapy for breast cancer.
Clinical trials to develop paclitaxel (Taxol)-containing combinations started in 1992 with several approaches to combine doxorubicin and paclitaxel. Schedule-dependent toxicity limited doses in the initial trials, although antitumor activity was high. More recently, a well-tolerated, highly effective doxorubicin/paclitaxel regimen was developed with the use of bolus anthracycline administration...
متن کاملMGBG–cisplatin combination chemotherapy against breast cancer
Worldwide, it is estimated that more than one million women are diagnosed with breast cancer every year, representing 14% of female cancer deaths [1], about 4,500 new cases being detected each year in Portugal. In the present study, the compound metylglyoxal bis(guanylhydrazone) (MGBG) [2], an inhibitor of S-adenosylL-methionine descarboxylase (SAMdc), was investigated as a potencial anti-cance...
متن کاملPaclitaxel and Cisplatin Combination Chemotherapy in Pretreated Breast Cancer.
PURPOSE A single institute trial of combination chemotherapy, with paclitaxel and cisplatin, in patients with metastatic breast cancer, having failed previous combination chemotherapy, was performed. MATERIALS AND METHODS Patients were only eligible for this study if there disease had progressed, following treatment with previous chemotherapy, in either an adjuvant or a metastatic setting. Pa...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer
سال: 1972
ISSN: 0008-543X,1097-0142
DOI: 10.1002/1097-0142(197212)30:6<1543::aid-cncr2820300621>3.0.co;2-v